HUM Quote, Financials, Valuation and Earnings

Amedisys has a net margin of -2.37% compared to Humana's net margin of -3.41%. Humana's return on equity of 7.25% beat Amedisys's return on equity of 3.71%.

Humana has a consensus price target of $297.47, signalling upside risk potential of 5.5%. On the other hand Amedisys has an analysts' consensus of $97.38 which suggests that it could grow by 6.64%. Given that Amedisys has higher upside potential than Humana, analysts believe Amedisys is more attractive than Humana.

Humana has a beta of 0.624, which suggesting that the stock is 37.637% less volatile than S&P 500. In comparison Amedisys has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.035%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.26%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $29.2B, which are larger than Amedisys quarterly revenues of $598.1M. Humana's net income of -$693M is lower than Amedisys's net income of -$20.4M. Notably, Humana's price-to-earnings ratio is 28.34x while Amedisys's PE ratio is 69.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.29x versus 1.29x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

CVS Health has a net margin of -2.37% compared to Humana's net margin of 1.68%. Humana's return on equity of 7.25% beat CVS Health's return on equity of 6.12%.

Humana has a consensus price target of $297.47, signalling upside risk potential of 5.5%. On the other hand CVS Health has an analysts' consensus of $72.46 which suggests that it could grow by 7.14%. Given that CVS Health has higher upside potential than Humana, analysts believe CVS Health is more attractive than Humana.

Humana has a beta of 0.624, which suggesting that the stock is 37.637% less volatile than S&P 500. In comparison CVS Health has a beta of 0.574, suggesting its less volatile than the S&P 500 by 42.622%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.26%. CVS Health offers a yield of 3.93% to investors and pays a quarterly dividend of $0.67 per share. Humana pays 35.71% of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $29.2B, which are smaller than CVS Health quarterly revenues of $97.7B. Humana's net income of -$693M is lower than CVS Health's net income of $1.6B. Notably, Humana's price-to-earnings ratio is 28.34x while CVS Health's PE ratio is 18.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.29x versus 0.23x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of -2.37% compared to Humana's net margin of 4.47%. Humana's return on equity of 7.25% beat Option Care Health's return on equity of 14.93%.

Humana has a consensus price target of $297.47, signalling upside risk potential of 5.5%. On the other hand Option Care Health has an analysts' consensus of $37.78 which suggests that it could grow by 15.18%. Given that Option Care Health has higher upside potential than Humana, analysts believe Option Care Health is more attractive than Humana.

Humana has a beta of 0.624, which suggesting that the stock is 37.637% less volatile than S&P 500. In comparison Option Care Health has a beta of 1.074, suggesting its more volatile than the S&P 500 by 7.353%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.26%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $29.2B, which are larger than Option Care Health quarterly revenues of $1.3B. Humana's net income of -$693M is lower than Option Care Health's net income of $60.1M. Notably, Humana's price-to-earnings ratio is 28.34x while Option Care Health's PE ratio is 26.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.29x versus 1.13x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx has a net margin of -2.37% compared to Humana's net margin of -0.24%. Humana's return on equity of 7.25% beat OptimizeRx's return on equity of -16.71%.

Humana has a consensus price target of $297.47, signalling upside risk potential of 5.5%. On the other hand OptimizeRx has an analysts' consensus of $10.33 which suggests that it could grow by 38.89%. Given that OptimizeRx has higher upside potential than Humana, analysts believe OptimizeRx is more attractive than Humana.

Humana has a beta of 0.624, which suggesting that the stock is 37.637% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.179, suggesting its more volatile than the S&P 500 by 17.909%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.26%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $29.2B, which are larger than OptimizeRx quarterly revenues of $32.3M. Humana's net income of -$693M is lower than OptimizeRx's net income of -$78K. Notably, Humana's price-to-earnings ratio is 28.34x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.29x versus 1.48x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.